After years of relying on 5FU, colorectal cancer clinicians now have a wealth of targeted therapies and combination protocols to choose from. The question is, what to use in which patients and when?
Related Articles
Impact Factor
Does a new model improve decisions about mismatch-repair genetic testing and Lynch syndrome identification?
Cutting Edge
Don’t shoot the driver! It’s about taxonomy more than targets
Senza categoria
Leave a Reply